Concepedia

Danièle Ouellet

DO

58

Publications

10.4K

Citations

33

H-Index

1987

Active since

Affiliations

GlaxoSmithKline (United States)(Current)

Research Triangle Park Foundation

Janssen (United States)

Pfizer (United States)

Janssen (Belgium)

Danièle Ouellet is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

1987–2023

58

Publications

58

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · New England Journal of Medicine · 2014 · 1.8K citations · Full text

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock et al. · The Lancet · 2012 · 928 citations · Full text

, , +7

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

Kevin B. Kim, Richard Kefford, Anna C. Pavlick et al. · Journal of Clinical Oncology · 2012 · 473 citations · Full text

Rows per page

1–5 of 58